Srinagar Magazine

Atrial Fibrillation Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Atrial Fibrillation Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

March 23
12:08 2023
Atrial Fibrillation Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Atrial Fibrillation pipeline constitutes 5+ key companies continuously working towards developing 5+ Atrial Fibrillation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Atrial Fibrillation Overview

Atrial Fibrillation (AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart’s two upper chambers (the atria) beat chaotically and irregularly-out of coordination with the two lower chambers (the ventricles) of the heart.

 

Atrial Fibrillation Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atrial Fibrillation Market.

 

The Atrial Fibrillation Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Atrial Fibrillation Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Atrial Fibrillation treatment therapies with a considerable amount of success over the years. Atrial Fibrillation Key players such as – Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others, are developing therapies for the Atrial Fibrillation treatment 
  • Atrial Fibrillation Emerging therapies such as – Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others are expected to have a significant impact on the Atrial Fibrillation market in the coming years.   
  • In December 2023, Bayer initiated a trial entitled “A Multicenter, International, Randomized, Active Comparator-controlled, Double-blind, Double-dummy, Parallel-group, 2-arm, Phase 3 Study to Compare the Efficacy and Safety of the Oral FXIa Inhibitor Asundexian (BAY 2433334) With Apixaban for the Prevention of Stroke or Systemic Embolism in Male and Female Participants Aged 18 Years and Older With Atrial Fibrillation at Risk for Stroke (OCEANIC-AF
  • In January 2020, Bayer initiated a PACIFIC-AF trial entitled “Multicenter, Randomized, Active Comparator controlled, Double-blind, Double-dummy, Parallel Group, Dose-finding Phase 2 Study to Compare the Safety of the Oral FXIa Inhibitor BAY2433334 to Apixaban in Patients With Atrial Fibrillation”

 

Route of Administration

Atrial Fibrillation pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

 

Atrial Fibrillation Pipeline Therapeutics Assessment

  • Atrial Fibrillation Assessment by Product Type
  • Atrial Fibrillation By Stage and Product Type
  • Atrial Fibrillation Assessment by Route of Administration
  • Atrial Fibrillation By Stage and Route of Administration
  • Atrial Fibrillation Assessment by Molecule Type
  • Atrial Fibrillation by Stage and Molecule Type

 

DelveInsight’s Atrial Fibrillation Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the Atrial Fibrillation Therapeutics Market include:

Key companies developing therapies for Atrial Fibrillation are – Abbott Laboratories, Johnson & Johnson, Atricure Inc., Microport Scientific Corporation, Boston Scientific Corporation, St. Jude medical, Inc., Medtronic Plc, Koninklijke Philips N.V., Siemens AG, and others.

 

Emerging Atrial Fibrillation Drugs Under Different Phases of Clinical Development Include:

  • Research programme: Thryv Therapeutics Inc.
  • CTP-Amio: Vivasc Therapeutics
  • VE 1902: Verseon
  • OMT 28: OMEICOS Therapeutics
  • Etripamil: Milestone Pharmaceuticals
  • HBI-3000: HUYA Bioscience
  • AP 30663: Acesion Pharma
  • HSY 244: Novartis
  • HBI-3000 (sulcardine sulfate trihydrate): HUYA Bioscience International
  • AGN-151607: AbbVie
  • Asundexian: Bayer AG
  • Inrhythm: InCarda Therapeutics, Inc.

 

Get a Free Sample PDF Report to know more about Atrial Fibrillation Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/atrial-fibrillation-pipeline-insight

 

Atrial Fibrillation Pipeline Analysis:

The Atrial Fibrillation pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Atrial Fibrillation with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atrial Fibrillation Treatment.
  • Atrial Fibrillation key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Atrial Fibrillation Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atrial Fibrillation market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Atrial Fibrillation product details are provided in the report. Download the Atrial Fibrillation pipeline report to learn more about the emerging Atrial Fibrillation therapies

 

Atrial Fibrillation Pipeline Market Drivers

  • Rising prevalence of Atrial fibrillation
  • Increase in the Adoption of Advanced Technologies

 

Atrial Fibrillation Pipeline Market Barriers

  • Complications associated with the use of Atrial fibrillation drugs
  • Lack of awareness regarding medical therapy in underdeveloped and developing regions

 

Scope of Atrial Fibrillation Pipeline Drug Insight    

  • Coverage: Global
  • Key Atrial Fibrillation Companies: Thryv Therapeutics Inc., Vivasc Therapeutics, Verseon, HUYA Bioscience, Novartis, AbbVie, Bayer AG, InCarda Therapeutics, Inc., and others
  • Key Atrial Fibrillation Therapies: Research programme, CTP-Amio, VE 1902, HBI-3000, HSY 244, AGN-151607, Asundexian, Inrhythm, and others
  • Atrial Fibrillation Therapeutic Assessment: Atrial Fibrillation current marketed and Atrial Fibrillation emerging therapies
  • Atrial Fibrillation Market Dynamics: Atrial Fibrillation market drivers and Atrial Fibrillation market barriers 

 

Request for Sample PDF Report for Atrial Fibrillation Pipeline Assessment and clinical trials

 

Table of Contents

1

Atrial Fibrillation Report Introduction

2

Atrial Fibrillation Executive Summary

3

Atrial Fibrillation Overview

4

Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment

5

Atrial Fibrillation Pipeline Therapeutics

6

Atrial Fibrillation Late Stage Products (Phase II/III)

7

Atrial Fibrillation Mid Stage Products (Phase II)

8

Atrial Fibrillation Early Stage Products (Phase I)

9

Atrial Fibrillation Preclinical Stage Products

10

Atrial Fibrillation Therapeutics Assessment

11

Atrial Fibrillation Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Atrial Fibrillation Key Companies

14

Atrial Fibrillation Key Products

15

Atrial Fibrillation Unmet Needs

16 

Atrial Fibrillation Market Drivers and Barriers

17

Atrial Fibrillation Future Perspectives and Conclusion

18

Atrial Fibrillation Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about Atrial Fibrillation drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting